We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOMZ:NASDAQTOMI Environmental Solutions, Inc. Analysis

Data as of 2026-06-23 - not real-time

$0.71

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: TOMZ is trading at $0.71, well below its 20‑day (0.87), 50‑day (0.76) and 200‑day (0.78) simple moving averages, with a bearish MACD histogram and an RSI of 40.9, indicating limited short‑term momentum. Fundamental stress: The company reports a negative operating margin (‑38%) and profit margin (‑75%), a massive debt‑to‑equity ratio (>620,000%), and a trailing EPS of –$0.22, while its forward PE of 17.6 sits comfortably below the industry average of 31.6. Valuation tension: A discounted cash‑flow model suggests a fair value of $0.49, implying the market price is modestly above intrinsic estimates, yet the price‑to‑book of 1.06 and forward PE hint at a potentially fair‑value trade.
Catalyst narrative: Recent regulatory approvals in Austria and Italy expand TOMI’s European footprint, and growing demand from the food‑safety and large‑event sectors (e.g., post‑Ebola, norovirus concerns) could unlock new revenue streams. However, the stock faces a 30‑day volatility of ~100% and decreasing volume, underscoring heightened market uncertainty. Investors should weigh the upside from market expansion against the deep‑seated balance‑sheet weakness and earnings volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below key moving averages and bearish MACD
  • Decreasing trading volume and high short‑term volatility
  • Negative earnings and heavy debt load

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Regulatory approvals expanding European market access
  • Growing demand from food safety and large‑event disinfection markets
  • Forward PE advantage relative to industry peers

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained balance‑sheet weakness and high debt‑to‑equity
  • Potential for stable cash generation if market expansion materializes
  • Continued exposure to sector volatility and macro‑economic cycles

Key Metrics & Analysis

Financial Health

Revenue Growth4.90%
Profit Margin-75.33%
P/E Ratio17.6
ROE-223.94%
ROA-26.74%
Debt/Equity620170.75
P/B Ratio1.1
Op. Cash Flow$-625403
Free Cash Flow$888.7K
Industry P/E31.6

Technical Analysis

TrendNeutral
RSI40.9
Support$0.67
Resistance$1.08
MA 20$0.87
MA 50$0.75
MA 200$0.78
MACDBearish
VolumeDecreasing
Fear & Greed Index86.45

Valuation

Fair Value$0.49
Target Price$3.50
Upside/Downside396.24%
GradeFair
TypeBlend

Risk Assessment

Beta0.11
Volatility100.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.